Phase II trial of co‐administration of CD19‐ and CD20‐targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Phase II trial of co‐administration of CD19‐ and CD20‐targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma
Authors
Keywords
-
Journal
Cancer Medicine
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2020-07-01
DOI
10.1002/cam4.3259
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Tumor Identification of Less Aggressive or Indolent Lymphoma With Whole-Body 11C-Acetate PET/CT
- (2019) Junichi Tsuchiya et al. CLINICAL NUCLEAR MEDICINE
- A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial
- (2019) Zhiling Yan et al. Lancet Haematology
- The efficacy and safety of anti-CD19/CD20 chimeric antigen receptor- T cells immunotherapy in relapsed or refractory B-cell malignancies:a meta-analysis
- (2018) Hui Zhou et al. BMC CANCER
- Updated safety and long term clinical outcomes in TRANSCEND NHL 001, pivotal trial of lisocabtagene maraleucel (JCAR017) in R/R aggressive NHL.
- (2018) Jeremy S. Abramson et al. JOURNAL OF CLINICAL ONCOLOGY
- Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
- (2018) Frederick L Locke et al. LANCET ONCOLOGY
- Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- (2018) Stephen J. Schuster et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prognostic impact of CD5 expression in diffuse large B-cell lymphoma in patients treated with rituximab-EPOCH
- (2017) Beenu Thakral et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- CUDC-907 in relapsed/refractory diffuse large B-cell lymphoma, including patients with MYC-alterations: results from an expanded phase I trial
- (2017) Yasuhiro Oki et al. HAEMATOLOGICA
- Clinical Impact of the Cell-of-Origin Classification and the MYC/BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group
- (2017) Annette M. Staiger et al. JOURNAL OF CLINICAL ONCOLOGY
- CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy
- (2017) Terry J Fry et al. NATURE MEDICINE
- Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
- (2017) Sattva S. Neelapu et al. NEW ENGLAND JOURNAL OF MEDICINE
- CUDC-907 in relapsed/refractory diffuse large B-cell lymphoma, including patients with MYC-alterations: results from an expanded phase I trial
- (2017) Yasuhiro Oki et al. HAEMATOLOGICA
- Toxicities of chimeric antigen receptor T cells: recognition and management
- (2016) Jennifer N. Brudno et al. BLOOD
- CD19 CAR–T cells of defined CD4+:CD8+ composition in adult B cell ALL patients
- (2016) Cameron J. Turtle et al. JOURNAL OF CLINICAL INVESTIGATION
- Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study
- (2016) Alexander M. Lesokhin et al. JOURNAL OF CLINICAL ONCOLOGY
- Outcome of patients with primary refractory diffuse large B cell lymphoma after R-CHOP treatment
- (2015) Felicitas Hitz et al. ANNALS OF HEMATOLOGY
- Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study
- (2015) E Van Den Neste et al. BONE MARROW TRANSPLANTATION
- Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo
- (2015) D Sommermeyer et al. LEUKEMIA
- Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma
- (2015) Wyndham H Wilson et al. NATURE MEDICINE
- Current concepts in the diagnosis and management of cytokine release syndrome
- (2014) D. W. Lee et al. BLOOD
- Randomized Comparison of Gemcitabine, Dexamethasone, and Cisplatin Versus Dexamethasone, Cytarabine, and Cisplatin Chemotherapy Before Autologous Stem-Cell Transplantation for Relapsed and Refractory Aggressive Lymphomas: NCIC-CTG LY.12
- (2014) Michael Crump et al. JOURNAL OF CLINICAL ONCOLOGY
- Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification
- (2014) Bruce D. Cheson et al. JOURNAL OF CLINICAL ONCOLOGY
- Outcomes of patients with relapsed/refractory diffuse large B-cell lymphoma with progression of lymphoma after autologous stem cell transplantation in the rituximab era
- (2013) Sarah J. Nagle et al. AMERICAN JOURNAL OF HEMATOLOGY
- Ofatumumab in combination with ICE or DHAP chemotherapy in relapsed or refractory intermediate grade B-cell lymphoma
- (2013) M. J. Matasar et al. BLOOD
- Patient age at diagnosis is associated with the molecular characteristics of diffuse large B-cell lymphoma
- (2012) W. Klapper et al. BLOOD
- The proportion of activated B-cell like subtype among de novo diffuse large B-cell lymphoma increases with age
- (2011) S. Mareschal et al. HAEMATOLOGICA
- Salvage chemotherapy and autologous stem cell transplant in primary refractory diffuse large B-cell lymphoma: outcomes and prognostic factors
- (2011) David Telio et al. LEUKEMIA & LYMPHOMA
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search